Stoke Therapeutics, Inc. (STOK)
STOK Stock Price Chart
Explore Stoke Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze STOK price movements and trends.
STOK Company Profile
Discover essential business fundamentals and corporate details for Stoke Therapeutics, Inc. (STOK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jun 2019
Employees
128.00
CEO
Ian F. Smith
Description
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
STOK Financial Timeline
Browse a chronological timeline of Stoke Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.82, while revenue estimate is $4.89m.
Earnings released on 7 May 2026
EPS came in at -$0.79 surpassing the estimated -$0.80 by +1.25%, while revenue for the quarter reached $6.23m , missing expectations by -3.92%.
Earnings released on 16 Mar 2026
EPS came in at -$0.97 falling short of the estimated -$0.75 by -29.33%, while revenue for the quarter reached $1.40m , missing expectations by -75.97%.
Earnings released on 4 Nov 2025
EPS came in at -$0.65 falling short of the estimated -$0.54 by -20.37%, while revenue for the quarter reached $10.63m , beating expectations by +133.39%.
Earnings released on 12 Aug 2025
EPS came in at -$0.40 surpassing the estimated -$0.57 by +29.82%, while revenue for the quarter reached $13.82m , beating expectations by +157.99%.
Earnings released on 13 May 2025
EPS came in at $1.90 surpassing the estimated -$0.37 by +613.51%, while revenue for the quarter reached $158.57m , beating expectations by +403.19%.
Earnings released on 18 Mar 2025
EPS came in at -$0.18 surpassing the estimated -$0.51 by +64.71%, while revenue for the quarter reached $22.61m , beating expectations by +485.85%.
Earnings released on 5 Nov 2024
EPS came in at -$0.47 surpassing the estimated -$0.52 by +9.62%, while revenue for the quarter reached $4.89m , beating expectations by +16.52%.
Earnings released on 7 Aug 2024
EPS came in at -$0.46 surpassing the estimated -$0.57 by +19.30%, while revenue for the quarter reached $4.83m , beating expectations by +48.19%.
Earnings released on 6 May 2024
EPS came in at -$0.57 surpassing the estimated -$0.60 by +5.00%, while revenue for the quarter reached $4.22m , beating expectations by +31.34%.
Earnings released on 25 Mar 2024
EPS came in at -$0.60 surpassing the estimated -$0.62 by +3.23%, while revenue for the quarter reached $2.80m , missing expectations by -13.78%.
Earnings released on 7 Nov 2023
EPS came in at -$0.55 surpassing the estimated -$0.65 by +15.38%, while revenue for the quarter reached $3.31m , beating expectations by +1.78%.
Earnings released on 7 Aug 2023
EPS came in at -$0.69 falling short of the estimated -$0.65 by -6.15%, while revenue for the quarter reached $2.48m , missing expectations by -21.74%.
Earnings released on 4 May 2023
EPS came in at -$0.53 surpassing the estimated -$0.70 by +24.29%, while revenue for the quarter reached $5.15m , beating expectations by +71.73%.
Earnings released on 6 Mar 2023
EPS came in at -$0.65 surpassing the estimated -$0.72 by +9.72%, while revenue for the quarter reached $3.27m , beating expectations by +14.19%.
Earnings released on 14 Nov 2022
EPS came in at -$0.66 surpassing the estimated -$0.69 by +4.35%, while revenue for the quarter reached $2.91m , beating expectations by +6.71%.
Earnings released on 8 Aug 2022
EPS came in at -$0.63 surpassing the estimated -$0.70 by +10.00%, while revenue for the quarter reached $3.23m , beating expectations by +22.36%.
Earnings released on 10 May 2022
EPS came in at -$0.66 falling short of the estimated $0.61 by -208.20%, while revenue for the quarter reached $3.00m , missing expectations by -94.00%.
Earnings released on 10 Mar 2022
EPS came in at -$0.66 falling short of the estimated -$0.62 by -6.45%.
Earnings released on 8 Nov 2021
EPS came in at -$0.61 falling short of the estimated -$0.58 by -5.17%.
Earnings released on 10 Aug 2021
EPS came in at -$0.60 falling short of the estimated -$0.49 by -22.45%.
STOK Stock Performance
Access detailed STOK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
